Verastem Oncology (VSTM)
3.71
-0.15 (3.89%)
Upcoming Events
Latest Headlines
FDA grants fast track status to Verastem's lung cancer drug VS-7375
June 3, 2026 4:01 PM - StreetInsider
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally
June 3, 2026 4:01 PM - BizWire
Form S-8 Verastem, Inc.
May 29, 2026 4:41 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: BAILEY MICHAEL P
May 27, 2026 5:46 PM - SEC Filing
Form 3 Verastem, Inc. For: May 21 Filed by: BAILEY MICHAEL P
May 27, 2026 5:44 PM - SEC Filing
Form 144 Verastem, Inc. Filed by: Gagnon Robert E.
May 27, 2026 4:48 PM - SEC Filing
Verastem Oncology to Present at Jefferies Healthcare Conference
May 27, 2026 7:30 AM - BizWire
Form 4 Verastem, Inc. For: May 21 Filed by: Tollefson Karin Anna
May 26, 2026 6:24 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: Stuglik Brian M
May 26, 2026 6:22 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: Rowinsky Eric K
May 26, 2026 6:21 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: ROBERTSON MICHELLE
May 26, 2026 6:20 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: Kapur Anil
May 26, 2026 6:18 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: Bunn Paul A.
May 26, 2026 6:13 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: JOHNSON JOHN
May 26, 2026 6:12 PM - SEC Filing
Form 8-K Verastem, Inc. For: May 21
May 26, 2026 8:15 AM - SEC Filing
Verastem Oncology appoints Michael Bailey to board of directors
May 26, 2026 7:30 AM - StreetInsider
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
May 26, 2026 7:30 AM - BizWire
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Foresite Capital Fund VI LP
May 15, 2026 4:30 PM - SEC Filing
Form SCHEDULE 13G/A Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:08 AM - SEC Filing
Form SCHEDULE 13G/A Verastem, Inc. Filed by: RTW INVESTMENTS, LP
May 15, 2026 8:43 AM - SEC Filing
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
May 15, 2026 6:36 AM - SEC Filing
Verastem (VSTM) PT Lowered to $14 at Mizuho
May 14, 2026 6:38 AM - StreetInsider
Verastem Oncology to Present at Upcoming Investor Conferences
May 12, 2026 7:30 AM - BizWire
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
May 8, 2026 7:30 AM - BizWire
Verastem (VSTM) PT Lowered to $18 at BTIG
May 8, 2026 6:56 AM - StreetInsider
Verastem Oncology (VSTM) Misses Q1 EPS by 43c
May 7, 2026 4:24 PM - StreetInsider
Form 8-K Verastem, Inc. For: May 07
May 7, 2026 4:14 PM - SEC Filing
Form 10-Q Verastem, Inc. For: Mar 31
May 7, 2026 4:09 PM - SEC Filing
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 7, 2026 4:01 PM - BizWire
Form 4 Verastem, Inc. For: May 04 Filed by: Paterson Dan
May 6, 2026 4:01 PM - SEC Filing
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
April 30, 2026 7:30 AM - BizWire
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026 7:30 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
April 13, 2026 6:41 AM - StreetInsider
BTIG on Verastem (VSTM): data supports drug's ~$1B peak sales potential
April 10, 2026 12:26 PM - StreetInsider
Verastem presents two-year follow-up data for ovarian cancer therapy
April 10, 2026 7:00 AM - StreetInsider
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the S
April 10, 2026 7:00 AM - BizWire
Form DEF 14A Verastem, Inc. For: May 21
April 9, 2026 4:16 PM - SEC Filing
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026 4:05 PM - BizWire
Verastem (VSTM) PT Lowered to $15 at Jefferies
March 27, 2026 4:17 PM - StreetInsider
Form SCHEDULE 13G/A Verastem, Inc. Filed by: VANGUARD GROUP INC
March 27, 2026 1:52 PM - SEC Filing
Form 4 Verastem, Inc. For: Mar 20 Filed by: Calkins Daniel
March 23, 2026 5:20 PM - SEC Filing
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
March 17, 2026 6:03 PM - BizWire
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 An
March 17, 2026 4:44 PM - BizWire
BTIG Assumes Verastem (VSTM) at Buy
March 11, 2026 4:06 PM - StreetInsider
Full Article List
